Page 168 - CW E-Magazine (17-12-2024)

News from Abroad

REDUCING ENVIRONMENTAL IMPACT
CordenPharma submits near-term GHG emission reduction

targets to the SBTi

After joining the Science-Based mental impact transparent, the cal- Colorado, USA site, CordenPharma has
Target initiative (SBTi) in December culated carbon footprint was reported already taken important steps towards
2022, Swiss CDMO, CordenPharma, through the environmental disclosure its climate ambitions.
has announced the submission of its system of CDP, formerly known as the
near-term greenhouse gas (GHG) emis- Carbon Disclosure Project. This pub- Dr. Michael Quirmbach, President &
sion reduction targets to the SBTi in lished environmental data is often CEO of the CordenPharma Group
November 2024 for approval and utilised by disclosers, capital markets, commented, “Taking more pro-active
validation. customers, and other stakeholders to carbon emission reduction actions en-
make informed decisions and drive action. hances our competitiveness in the tran-
To set climate objectives, Corden- sition to a low-carbon economy and the
Pharma calculated its carbon footprint CordenPharma set its near-term cli- collaboration with customers in achiev-
from the base year 2023 using the GHG mate objectives and a global decarboni- ing their climate change goals.”
protocol methodology. Under the GHG sation strategy to achieve them over
protocol, GHG emissions are catego- the next decade in collaboration with In 2022, CordenPharma was acquired
rised into three different scopes, de- a third-party consultancy. With photo- by Astorg, a leading pan-European
pending on whether they are generated voltaics already installed at its Lisbon, private equity firm to support the growth
from an entity’s own operations or from Portugal and Fribourg, Switzerland and development of the company.
their value chain partners. sites, biogas used at the Liestal, Switzerland Through this partnership, Astorg’s ESG
facility, and the investment into an team collaborates with CordenPharma to
To make CordenPharma’s environ- offsite solar electricity park for the accelerate its sustainable journey.
MARKETING SUPPORT
Brenntag to distribute K+S’ high-purity salts for

pharmaceutical applications

Brenntag, the German chemicals distri-
butor, has announced a new partner-
ship with Germany’s K+S Minerals and
Agriculture GmbH for the worldwide
distribution of three pharmaceutical salts.

K+S is one of the world’s largest
producers of pharmaceutical salts and
produces its high-purity sodium chlo-
ride and potassium chloride at several
European sites. Brenntag will now
distribute three of their salts in the
pharmaceutical market: Apisal sodium copoeias (European Pharmacopoeia, commitment to providing these impor-
chloride GMP grade (in pharmacopoeia US Pharmacopeia). tant ingredients ensures that our customers
quality, API), potassium chloride worldwide have access to the highest
99.9 % KCl Ph. Eur., USP (API) and “By adding K+S’ pharmaceutical quality components needed to produce
HD-NaCl (excipient grade). The salts salts, such as Sodium and Potassium effective pharmaceuticals, electrolyte
are manufactured using special processes Chloride, to our portfolio, we are therapies and dietary supplements,”
to ensure purity and meeting the strict strengthening our role as a key supplier commented Mr. Torsten Walz, Global
quality requirements of the pharma to the global healthcare industry. Our President Brenntag Specialties Pharma.

168 Chemical Weekly December 17, 2024

Contents Index to Advertisers Index to Products Advertised